OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear

787 Projects | 542 Researchers | $367,651,933 Invested

2024

Alamar Biosciences

Xiao-Jun Ma, PhD

Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases

  • Funding Amount: $10,016,094
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

Polku Therapeutics

Timo Myöhänen, PhD

Novel prolyl oligopeptidase ligands to target Tau in frontotemporal dementia and other tauopathies

  • Funding Amount: $282,600
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2024

ViewMind

Yaakov Stern, PhD

Investigating ViewMind ocular digital cognitive biomarkers and their relationship to tau and amyloid PET scans.

  • Funding Amount: $1,429,119
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Status: Active

2024

NSC-Therapeutics GmbH

Manfred Windisch, PhD

A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease

  • Funding Amount: $4,998,336
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active

2024

Aquinnah Pharmaceuticals

Glenn Larsen, PhD

Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology.

  • Funding Amount: $2,999,586
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2024

C2N Diagnostics

Joel Braunstein, MD, MBA

Validation of a Mass Spectrometry-Based Clinical Lab Workstation and Global Scale-up of Precivity(TM) In-Vitro Diagnostic Testing

  • Funding Amount: $7,025,121
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

Stichting Amsterdam UMC

Betty Tijms

Plasma proteomic approach to identify CSF defined molecular subtypes of Alzheimer’s disease for personalised treatment

  • Funding Amount: $650,000
  • Organization Type: Academic/Nonprofit
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2024

University of Gothenburg

Henrik Zetterberg, MD, PhD

Certified Reference Material and Method for plasma p-tau217

  • Funding Amount: $1,117,740
  • Organization Type: Academic/Nonprofit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

UsAgainstAlzheimer's

Ben Tiede, PhD MPP

CEOi Digital Cognitive Assessments Workgroup

  • Funding Amount: $50,000
  • Organization Type: Academic/Nonprofit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

University of Minnesota

Karen Ashe, MD, PhD

Targeting Caspase-2 to Repair Synaptic Function in Tauopathies

  • Funding Amount: $493,875
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active
View More